• metastatic/advanced hepatocellular cancer (mHCC)
• mHCC - (neo)adjuvant (NA) 3
• mHCC - 1st line (L1) 10
• mHCC - 2nd line (L2) 2
• lung cancer : non small cell (NSCLC) 5

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus bevacizumab
• durvalumab based treatment
• durvalumab alone
• nivolumab based treatment
• nivolumab alone
• sintilimab based treatment
• sintilimab
• Immune checkpoint association
• nivolumab plus ipilimumab

• versus all
• vs chemotherapy
• vs Standard of Care (SoC)
• vs immune chekpoint inhibitors
• vs anti-PD-(L)1
• vs nivolumab based treatment
• vs nivolumab alone
• vs non active control
• vs placebo

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)